Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema

Inclusion Criteria: * Read, understood and signed the Informed Consent form * Meets indications for use per the IFU * Bilateral heterogeneous and/or homogeneous emphysema * Post bronchodilator 15% predicted ≤ Forced Expiratory Volume in 1 second (FEV1) ≤ 45% predicted * Post bronchodilator Residual Volume (RV) ≥ 200% predicted * Post bronchodilator Total Lung Capacity (TLC) \>100% pred. * Post bronchodilator RV/TLC \> 55% * Dyspnea related to hyperinflation scored ≥ 2 on modified Medical Research Council (mMRC) dyspnea scale despite optimal medical management * Receiving optimal drug therapy and medical management according to clinical practice. * Performing regular physical activity, at least 2 times per week * Stopped smoking as confirmed by carboxyhemoglobin (CoHB) * 100m ≤ 6 minute walk distance (6MWD) ≤ 450m * Deemed eligible per Eligibility Review Committee (ERC) * if treated in France, subject must be entitled to French social security. Exclusion Criteria: * Known sensitivity to drugs required for performing bronchoscopy or in whom bronchoscopic procedures are contraindicated * Evidence of active infection in the lungs * Hypersensitivity or allergy to nitinol (nickel-titanium) or its constituent metals * Clinical significant pulmonary fibrosis * Clinically significant, generalized bronchiectasis * Clinically significant bleeding disorders * Patient taking immunosuppressive drugs other than steroids (e.g., for the treatment of cancer, rheumatoid arthritis, autoimmune disease, or prevention of tissue or organ rejection). * Primary diagnosis of asthma * Two (2) or more COPD exacerbations in the prior year, or 1 or more COPD exacerbations in the prior 3 months with indication for hospitalization assessment, according to GOLD 2017 recommendations . * Predominant small airways disease defined as significant bronchiectasis with sputum production (\> 2 tablespoons daily) or significant bronchial wall thickening per High Resolution Computed Tomography (HRCT) * Percent Low Attenuation Area (%LAA) \< 20% in the most damaged lobe of either lung. * Computed Tomography (CT) Imaging consistent with active pulmonary infection, significant interstitial disease or pleural disease * Severe bullous disease (defined by bulla \> 8cm or 1/3 of lung volume, or single bullous defect \>8 cm) or predominant paraseptal emphysema \[defined by numerous large (\>1cm) paraseptal defects in the target lobe comprising of \>5% of total lung volume\]. * Lung pathology of nodule not proven stable or benign * Radiographic confirmation of atelectasis or other scarring/fibrosis in areas of intended Coil implant * Use of more than 20 mg/day prednisolone or equivalent dosage of a different corticosteroid * Severe pulmonary hypertension (Right Ventricular Systolic Pressure (RVSP) \> 50 mm Hg or other signs of Pulmonary Hypertension (PHT) with right ventricular dysfunction) * Severe hypercapnia (PaCO2 \> 55 mmHg on room air) and/or severe hypoxemia (PaO2 \< 45mm Hg on room air, High altitude criterion: PaO2 \< 30 mm Hg) * Previous Lung Volume Reduction (LVR) surgery, lung transplantation, lobectomy, LVR devices or other device to treat COPD in either lung. * Diagnosed with alpha-1 antitrypsin deficiency * Diffusion Capacity of the lungs for Carbon Monoxide (DLCO) \< 20 % * Significant, recent or unstable cardiac disease defined as severe heart failure (Left Ventricular Ejection Fraction (LVEF) \< 45% despite optimal medical management), unstable cardiac arrhythmia or coronary artery disease (angina on activity), or ischemic event in the past 6 months. * Body Mass Index (BMI) \> 30 * Participation in any other clinical Study. * Subject is pregnant or lactating, or plan to become pregnant within the study timeframe. * If treated in France, Subject is a "personnel vulnerable" as defined by French Regulation